13.00

5.78% +0.71

Pre-market: 12.54 -0.46 -3.54%

Cidara Therapeutics Inc (CDTX)

Overview News Price History Option Chain Discussions Forecast

Cidara Therapeutics Inc stock is currently priced at $13.00, with a 24-hour trading volume of 751.71K. It has seen a +5.78% increased in the last 24 hours and a +1,642% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $11.66 pivot point. If it approaches the $13.22 resistance level, significant changes may occur.

Previous Close:

$12.29

Open:

$14.5

24h Volume:

751.71K

Market Cap:

$59.30M

Revenue:

$56.54M

Net Income/Loss:

$-30.70M

P/E Ratio:

-33.33

EPS:

-0.39

Net Cash Flow:

$-31.05M

1W Performance:

+1,701%

1M Performance:

+1,642%

6M Performance:

+1,466%

1Y Performance:

+1,162%

1D Range:

$12.13

$14.96

52W Range:

$0.5002

$14.96

Cidara Therapeutics Inc Stock (CDTX) Company Profile

Name

Cidara Therapeutics Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

858-752-6170

Address

6310 Nancy Ridge Drive, Suite 101, San Diego, CA

Employee

Twitter

@CidaraThera

Next Earnings Date

2024-05-09

Latest SEC Filings

CDTX's Discussions on Twitter

Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-21	Resumed	H.C. Wainwright	Buy
Sep-22-21	Upgrade	WBB Securities	Buy → Strong Buy
Mar-04-21	Initiated	Aegis Capital	Buy
Sep-04-19	Upgrade	Wedbush	Neutral → Outperform
Jul-26-18	Initiated	Citigroup	Buy
Apr-21-17	Initiated	Raymond James	Strong Buy
Apr-17-17	Reiterated	H.C. Wainwright	Buy
Apr-12-17	Initiated	Ladenburg Thalmann	Buy
Apr-11-17	Resumed	Wedbush	Outperform
Feb-22-17	Reiterated	H.C. Wainwright	Buy
Feb-22-17	Upgrade	WBB Securities	Sell → Hold
Dec-21-16	Resumed	Leerink Partners	Outperform
Dec-19-16	Initiated	H.C. Wainwright	Buy
Sep-23-16	Downgrade	WBB Securities	Hold → Sell
Oct-09-15	Upgrade	WBB Securities	Sell → Hold
May-11-15	Initiated	Jefferies	Buy
May-11-15	Initiated	Leerink Partners	Outperform
May-11-15	Initiated	Needham	Buy
May-11-15	Initiated	Wedbush	Outperform
Apr-23-15	Initiated	WBB Securities	Sell

View All

Cidara Therapeutics Inc Stock (CDTX) Latest News

Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline

GlobeNewswire Inc.

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire Inc.

Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice

GlobeNewswire Inc.

Cidara Therapeutics Announces Reverse Stock Split

GlobeNewswire Inc.

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

GlobeNewswire Inc.

TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Cidara Therapeutics Inc Stock (CDTX) Financials Data

Cidara Therapeutics Inc (CDTX) Revenue 2024

CDTX reported a revenue (TTM) of $56.54 million for the quarter ending September 30, 2023, a -7.75% decline year-over-year.

Cidara Therapeutics Inc (CDTX) Net Income 2024

CDTX net income (TTM) was -$30.70 million for the quarter ending September 30, 2023, a +7.61% increase year-over-year.

Cidara Therapeutics Inc (CDTX) Cash Flow 2024

CDTX recorded a free cash flow (TTM) of -$31.05 million for the quarter ending September 30, 2023, a -38.07% decrease year-over-year.

Cidara Therapeutics Inc (CDTX) Earnings per Share 2024

CDTX earnings per share (TTM) was -$0.39 for the quarter ending September 30, 2023, a +29.09% growth year-over-year.

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.